Cantor Fitzgerald Predicts Stronger Earnings for Korro Bio

Korro Bio, Inc. (NASDAQ:KRRO) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Korro Bio in a research report issued to clients and investors on Thursday, November 13th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings per share of ($9.70) for the year, up from their prior forecast of ($10.49). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. Cantor Fitzgerald also issued estimates for Korro Bio’s FY2026 earnings at ($5.04) EPS.

Other equities analysts have also issued reports about the company. HC Wainwright reissued a “neutral” rating on shares of Korro Bio in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research report on Tuesday, October 14th. Wall Street Zen raised shares of Korro Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Jones Trading cut Korro Bio from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Royal Bank Of Canada lowered shares of Korro Bio from an “outperform” rating to a “sector perform” rating in a research report on Thursday. One research analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Korro Bio has an average rating of “Hold” and an average price target of $76.00.

Korro Bio Trading Down 6.6%

Shares of KRRO stock opened at $6.07 on Monday. The stock has a 50-day moving average of $37.71 and a 200-day moving average of $23.47. The stock has a market cap of $57.18 million, a price-to-earnings ratio of -0.65 and a beta of 2.94. Korro Bio has a 1-year low of $5.70 and a 1-year high of $56.69.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.61) by $0.69. The firm had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $0.41 million. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently bought and sold shares of the stock. Driehaus Capital Management LLC raised its position in shares of Korro Bio by 17.7% during the first quarter. Driehaus Capital Management LLC now owns 582,449 shares of the company’s stock valued at $10,140,000 after buying an additional 87,544 shares during the last quarter. Vanguard Group Inc. increased its position in Korro Bio by 2.3% during the third quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock valued at $18,948,000 after acquiring an additional 8,921 shares during the last quarter. Cormorant Asset Management LP purchased a new stake in Korro Bio in the 1st quarter worth about $6,621,000. JPMorgan Chase & Co. lifted its stake in shares of Korro Bio by 6,185.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after acquiring an additional 196,079 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Korro Bio by 10.8% in the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock worth $1,941,000 after purchasing an additional 15,166 shares during the last quarter. 13.18% of the stock is owned by hedge funds and other institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).